Introduction to Renal Trials

What is/are Renal Trials?

Renal Trials - While not primarily emphasized in clinical trials, evidence in other studies suggests that SGLT2i may confer retinoprotective effects via some of the same mechanisms in the aforementioned cardiorenal trials. ^[1] This was a retrospective study of children younger than 24 months on HD and PD in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry between January 1992 and December 2018. ^[2] Over the last several decades, major adverse clinical outcomes have been studied in the form of composite endpoints in cardiovascular and renal trials. ^[3] The recent CV and renal trials enriched our knowledge about the natural history of HF and CKD in T2D and provided evidence for the benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in HF and renal decline prevention. ^[4] SETTING & PARTICIPANTS Children and adolescents age 6-20 years with LN (N=231) and NLGD (N=1,726) who initiated maintenance dialysis 1991-2018 and enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. ^[5] Finally, it outlines the need for a cardiorenal education track that will guide future cardiorenal trials and integrate the clinical and research needs of this important field in the future. ^[6] Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN. ^[7] Here, the authors discuss how innovations in trial design and conduct could help achieve the goal of conducting a greater number of larger renal trials. ^[8] The established clinical endpoints for renal trials; doubling of serum creatinine or end-stage renal disease, are late manifestations of CKD. ^[9]

Larger Renal Trials

Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN. ^[1] Here, the authors discuss how innovations in trial design and conduct could help achieve the goal of conducting a greater number of larger renal trials. ^[2]

Pediatric Renal Trials

This was a retrospective study of children younger than 24 months on HD and PD in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry between January 1992 and December 2018. ^[1] SETTING & PARTICIPANTS Children and adolescents age 6-20 years with LN (N=231) and NLGD (N=1,726) who initiated maintenance dialysis 1991-2018 and enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. ^[2]